ALSO NOTED: Congress attacks FDA labeling idea; Abbott profits on surging Humira, Depakote sales;

> Dingell watch: In what's becoming an almost daily event, the House Energy and Commerce Committee sent a letter to the FDA, this time complaining of the agency's proposal to restrict drug-and-device companies' ability to add warnings to their product labels. Report

> Abbott Laboratories reported a $1.2 billion profit for the fourth quarter on stronger sales of its rheumatoid arthritis treatment Humira, epilepsy remedy Depakote, cholesterol fighter TriCor, and HIV drug Kaletra. Report

> Wyeth paid Wexler & Walker Public Policy Associates $380,000 in 2007 to lobby Congress and the Health and Human Services Department on drug approvals, reimbursement rates, and other healthcare issues. Report

> Johnson & Johnson launched its over-the-counter version of Zyrtec today, greeting aggressive marketing from Schering-Plough on behalf of its competing allergy drug, Claritin. Report

> Estée Lauder's Clinique brand and Botox-maker Allergan are teaming up on a new high-end skin care line to be sold in doctors' offices. Report

> A new survey shows that 19 percent of U.S. doctors refuse to see drug and device sales reps, and another 22.7 percent require reps to have an appointment. Report

> GlaxoSmithKline will start laying off all 236 employees at its plant in Bristol, England, in April. Report

> India's Cipla said third-quarter profits grew 14 percent to $53.7 million. Report

> American adults are largely ignoring a slate of important new vaccines that can prevent serious illness, according to a new survey from the National Foundation for Infectious Diseases. Report

And Finally... Wal-Mart is plotting a move into prescription benefits management, planning to negotiate contracts directly with employers to process and pay prescription drug claims. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.